A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

WASHINGTON, April 29 (Reuters) - The U.S. Supreme Court on Wednesday heard a patent dispute over a generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular drug Vascepa that could ...

The era of cheap, officially approved semaglutide is finally here—in Canada, that is. The country has just become the first in North America and the first G7 nation to license a generic version of the ...

Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...

If hyperlinks are not working in PDF files on your Windows 11/10 PC, you are not alone. Many users report this issue, and it often appears in different forms. For some, links appear clickable but do ...

Pharma major Lupin Ltd on Wednesday announced the launch of its generic version of anti-diabetic medicine dapagliflozin and metformin hydrochloride extended-release tablets in the US following ...

India’s pharma market expands on volumes, pricing, and chronic-led product momentum India’s pharmaceutical market sustained double-digit growth in March, with anti-diabetic therapies surging on the ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

The blockbuster weight loss drug sold as Ozempic and Wegovy will soon go generic in countries that are home to 40% of the world’s population, significantly lowering the price of a costly medicine that ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...